# US 2021/0340619 A1 · Compositions and methods for accurately identifying mutations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0340619 A1
- Document ID: US20210340619A1
- Status: Published application
- Kind: A1
- Application number: 17/374,917
- Filed: 2021-07-13
- Published: 2021-11-04
- Earliest claimed: 2012-02-17
- Assignees: Fred Hutchinson Cancer Research Center
- Applicants: Fred Hutchinson Cancer Research Center
- Inventors: Jason H. BIELAS
- Web page: https://patentgrep.com/patent/US20210340619A1

## CPC

- C12Q 1/6874: involving nucleic acid arrays, e.g. sequencing by hybridisation
- C12N 15/10: Processes for the isolation, preparation or purification of DNA or RNA (chemical preparation of DNA or RNA C07H21/00; preparation of non-structural polynucleotides from microorganisms or with enzymes C12P19/34)
- C12N 15/1065: {Preparation or screening of tagged libraries, e.g. tagged microorganisms by STM-mutagenesis, tagged polynucleotides, gene tags}
- C12N 15/1093: {General methods of preparing gene libraries, not provided for in other subgroups}
- C12N 15/70: Vectors or expression systems specially adapted for E. coli
- C12N 15/81: for yeasts
- C12N 15/85: for animal cells
- C12Q 1/6827: for detection of mutation or polymorphism
- C12Q 1/6869: Methods for sequencing
- C40B 40/08: Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
- C40B 50/06: Biochemical methods, e.g. using enzymes or whole viable microorganisms
- Y02E 50/10: Biofuels, e.g. bio-diesel
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C40B: COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES (in silico combinatorial libraries of nucleic acids, proteins or peptides G16B35/00; in silico combinatorial chemistry G16C20/60)
- Y02E: REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION

## Abstract

The present disclosure provides compositions and methods for accurately detecting mutations by uniquely tagging double stranded nucleic acid molecules with dual cyphers such that sequence data obtained from a sense strand can be linked to sequence data obtained from an anti-sense strand when sequenced, for example, by massively parallel sequencing methods.

## Claims

### Claim at position 1

-38. (canceled)

### Claim 39

A method for detecting mutations from exposure to a substance, the method comprising:
(a) preparing a sequencing library from a sample comprising a plurality of double-stranded DNA molecules from a patient exposed to the substance, wherein preparing the sequencing library comprises ligating cypher polynucleotides to the double-stranded DNA molecules to form double-stranded cypher-target nucleic acid complexes, wherein the cypher polynucleotides comprise identifier tags selected from a plurality of distinct identifier tag sequences;
(b) sequencing first and second strands of the cypher-target nucleic acid complexes to produce a plurality of first-strand sequencing reads and a plurality of second-strand sequencing reads;
(c) for each cypher-target nucleic acid complex among a plurality of the cypher-target nucleic acid complexes, comparing the first-strand sequencing reads with the second-strand sequencing reads to identify nucleotides in the first strand that have a corresponding complementary nucleotide in the second strand;
(d) detecting a mutation from exposure to the substance by analyzing an error-corrected sequence generated from the first strand sequencing reads and second strand sequencing reads for each of the cypher-target nucleic acid complexes among a plurality of the cypher-target nucleic acid complexes; and comparing the error-corrected sequences to a reference sequence to identify one or more of a mutation, a genomic distribution of mutations, a mutation frequency, sequence heterogeneity, or DNA damage.

### Claim 40 (depends on 39)

The method of claim 39, wherein the sample is derived from a human.

### Claim 41 (depends on 39)

The method of claim 39, wherein prior to preparing the sequencing library, the method further comprises exposing the patient to the substance.

### Claim 42 (depends on 41)

The method of claim 41, wherein prior to exposing the patient to the substance, the patient comprises a normal tissue.

### Claim 43 (depends on 39)

The method of claim 39, wherein the sample comprises a blood sample.

### Claim 44 (depends on 39)

The method of claim 39, wherein the identifier tag sequences comprise random or partially random sequences.

### Claim 45 (depends on 44)

The method of claim 44, wherein the random or partially random sequences comprise a length from about 5 nucleotides to about 10 nucleotides.

### Claim 46 (depends on 44)

The method of claim 44, wherein the identifier tags are double-stranded sequences.

### Claim 47 (depends on 39)

The method of claim 39, further comprising purifying a plurality of cypher-target nucleic acid complexes prior to sequencing, wherein the purified cypher-target nucleic acid complexes comprise nucleic acid molecules from specific genomic regions.

### Claim 48 (depends on 39)

The method of claim 39, wherein prior to sequencing, the method further comprises amplifying each strand of the cypher-target nucleic acid complexes to produce a set of copies of original first strands of the cypher-target nucleic acid complexes and a set of copies of complementary original second strands of the cypher-target nucleic acid complexes.

### Claim 49 (depends on 39)

The method of claim 39, wherein prior to comparing the first-strand sequencing reads with the second-strand sequencing reads, the method comprises grouping sequencing reads based on (i) the identifier tag sequences and (ii) sequence information from the double-stranded DNA molecules.

### Claim 50 (depends on 39)

The method of claim 39, wherein each of the error-corrected sequences has only nucleotide bases at which the majority of first strand sequencing reads and second strand sequencing reads are in agreement.

### Claim 51 (depends on 50)

The method of claim 50, wherein the method comprises calculating a mutation frequency among the plurality of double-stranded DNA molecules.

### Claim 52 (depends on 51)

The method of claim 51, wherein the mutations are transition mutations.

### Claim 53 (depends on 50)

The method of claim 50, wherein a sequence difference between the error-corrected sequence and the reference sequence is identified as a true mutation.

### Claim 54 (depends on 53)

The method of claim 53, wherein the true mutation is a substitution or insertion mutation type.

### Claim 55 (depends on 53)

The method of claim 53, wherein the true mutation is a transition mutation.

### Claim 56 (depends on 50)

The method of claim 50, wherein the error-corrected sequences map to the reference sequence, and the method further comprises identifying a distribution of mutations in the double-stranded DNA molecules.

### Claim 57 (depends on 54)

The method of claim 54, wherein the error-corrected sequences map to the reference sequence, and the method further comprises identifying a distribution of mutation types in the double-stranded DNA molecules.

### Claim 58 (depends on 39)

The method of claim 39, wherein the error corrected sequence is generated by distinguishing erroneous nucleotides in one strand that lack a matched base change in the complementary strand, and wherein the erroneous nucleotides are the result of systematic or biological errors in one strand.

### Claim 59 (depends on 39)

The method of claim 39, wherein the method comprises determining a genomic distribution of mutations with respect to the reference sequence.

### Claim 60

A method of identifying effects of DNA damaging compounds, the method comprising:
(a) providing a sample comprising a plurality of double-stranded DNA molecules from a patient that has been treated with a compound;
(b) preparing a sequencing library from the sample by ligating cypher polynucleotides to the double-stranded DNA molecules to form double-stranded cypher-target nucleic acid complexes, wherein the cypher polynucleotides comprise identifier tags selected from a plurality of distinct identifier tag sequences;
(c) for each cypher-target nucleic acid complex among a plurality of the cypher-target nucleic acid complexes, generating a set of copies of a first strand of the cypher-target nucleic acid complex and a set of distinct yet related copies of a complementary second strand of the cypher-target nucleic acid complex;
(d) sequencing one or more copies of the first and complementary second strands to produce a plurality of first-strand sequencing reads and a plurality of distinct yet related second-strand sequencing reads;
(e) for each cypher-target nucleic acid complex among a plurality of the cypher-target nucleic acid complexes, comparing the first-strand sequencing reads with the second-strand sequencing reads to identify nucleotides in the first strand that have a corresponding complementary nucleotide in the second strand;
(f) comparing an error-corrected sequence generated from the first strand sequencing reads and second strand sequencing reads to a reference sequence to determine one or more of a mutation, a genomic distribution of mutations, a mutation frequency, sequence heterogeneity, or DNA damage; and
(g) based on the comparing step, identifying DNA damage from the compound.

### Claim 61 (depends on 60)

The method of claim 60, wherein the error corrected sequence is generated by distinguishing erroneous nucleotides in one strand that lack a matched base change in the complementary strand, and wherein the erroneous nucleotides are the result of systematic or biological errors in one strand.

### Claim 62 (depends on 60)

The method of claim 60, wherein step (a) further comprises providing a plurality of samples from a plurality of patients treated with the compound.

### Claim 63 (depends on 60)

The method of claim 60, further comprising purifying a plurality of cypher-target nucleic acid complexes prior to sequencing, wherein the purified cypher-target nucleic acid complexes comprise nucleic acid molecules from specific genomic regions, and wherein the specific genomic regions comprise mutations common to most cells of a tumor.

### Claim 64 (depends on 60)

The method of claim 60, wherein the double-stranded DNA molecules comprise a deaminated cytosine.

### Claim 65 (depends on 64)

The method of claim 64, wherein the method further comprises enzymatically treating the double-stranded DNA molecules to repair damaged ends thereof prior to the ligating.
